stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Book value per share
Kymera Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 18.7×, up 67.9% from 11.1× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 16.1×. Over the past ten years it has ranged from 0.9× (fiscal 2018) to 20.4× (fiscal 2019); the current reading is higher than 88% of that period. Kymera Therapeutics, Inc. ranks 49th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 18.7× | 67.90% |
| FY2024 | 11.1× | 64.54% |
| FY2023 | 6.8× | (25.54%) |
| FY2022 | 9.1× | (5.11%) |
| FY2021 | 9.6× | (41.46%) |
| FY2020 | 16.4× | (19.83%) |
| FY2019 | 20.4× | 2,230.54% |
| FY2018 | 0.9× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 16.1× | 4.92% |
| Jun 2026 | 15.4× | (2.62%) |
| Mar 2026 | 15.8× | (15.57%) |
| Dec 2025 | 18.7× | 72.49% |
| 25 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | 32.3× |
| PCVX Vaxcyte, Inc. compare | 19.1× |
| KYMR Kymera Therapeutics, Inc. | 16.1× |
| TECH Bio-Techne Corp compare | 13.5× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| SMMT Summit Therapeutics PLC compare | 0.8× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement